Attachment 3g_Donor Report

HIV Rapid Testing MPEP September 2009

Panel and Vial Designations, CDC Donor Bulk Numbers,

CDC HIV Rapid Test Results and Donor HIV Status

Panel Vial CDC Donor CDC Test Donor HIV Laboratory Interpretation²

Letter Label Bulk Number Result^1,3 Status and/or Results

Test Result Interpretation

A A1 27 Negative (N) Uninfected __________ ____________

A2 13 Positive (S) Infected __________ ____________

A3 23 Positive (W) Infected __________ ____________

A4 13* Positive (S) Infected __________ ____________

A5 23* Positive (W) Infected __________ ____________

A6 24 Positive (W) Infected __________ ____________

B B1 13 Positive (S) Infected __________ ____________

B2 27 Negative (N) Uninfected __________ ____________

B3 23 Positive (W) Infected __________ ____________

B4 23* Positive (W) Infected __________ ____________

B5 24 Positive (W) Infected __________ ____________

B6 13* Positive (S) Infected __________ ____________

C C1 23 Positive (W) Infected __________ ____________

C2 24 Positive (W) Infected __________ ____________

C3 27 Negative (N) Uninfected __________ ____________

C4 13 Positive (S) Infected __________ ____________

C5 13* Positive (S) Infected __________ ____________

C6 23* Positive (W) Infected __________ ____________

D D1 23 Positive (W) Infected __________ ____________

D2 13 Positive (S) Infected __________ ____________

D3 13* Positive (S) Infected __________ ____________

D4 27 Negative (N) Uninfected __________ ____________

D5 23* Positive (W) Infected __________ ____________

D6 24 Positive (W) Infected __________ ____________

* Duplicate donors

¹ The CDC result was obtained after pre-shipment testing for the presence of HIV-1 Antibody with all commercially available HIV Rapid Testing kits licensed by the Food and Drug Administration (FDA) and with selected FDA-licensed Enzyme Immunoassay (EIA) kits. The CDC result is consistent with the manufacturers’ criteria for interpretation of results.

2. Laboratory Interpretation space (to be completed by participant laboratory) provided to facilitate comparison of participant laboratory

result with CDC result.

2. Strong (S) and Weak (W) designations are based on qualitative observations of the colorimetric test results for reactive samples.